SANES

11.812

-1.2%↓

BBVA

21.43

-0.37%↓

BNP

102.6

+0.45%↑

CABK

12.23

-2.82%↓

INGA

27.395

-1.37%↓

SANES

11.812

-1.2%↓

BBVA

21.43

-0.37%↓

BNP

102.6

+0.45%↑

CABK

12.23

-2.82%↓

INGA

27.395

-1.37%↓

SANES

11.812

-1.2%↓

BBVA

21.43

-0.37%↓

BNP

102.6

+0.45%↑

CABK

12.23

-2.82%↓

INGA

27.395

-1.37%↓

SANES

11.812

-1.2%↓

BBVA

21.43

-0.37%↓

BNP

102.6

+0.45%↑

CABK

12.23

-2.82%↓

INGA

27.395

-1.37%↓

SANES

11.812

-1.2%↓

BBVA

21.43

-0.37%↓

BNP

102.6

+0.45%↑

CABK

12.23

-2.82%↓

INGA

27.395

-1.37%↓

Search

Ipsen SA.

Abrir

SetorFinanças

162.4 -1.04

Visão Geral

Variação de preço das ações

24h

Atual

Mín

162

Máximo

165.2

Indicadores-chave

By Trading Economics

Rendimento

-225M

110M

Vendas

36M

1.9B

P/E

Médio do Setor

29.549

22.989

Rendimento de Dividendos

0.89

Margem de lucro

5.899

Funcionários

5,535

EBITDA

-171M

466M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

-4.26% downside

Dividendos

By Acuity

Rendimento de Dividendos

Médio do Setor

0.89%

4.69%

Próximos Ganhos

30 de jul. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.6B

13B

Abertura anterior

163.44

Fecho anterior

162.4

Sentimento de Notícias

By Acuity

25%

75%

41 / 439 Ranking em Finance

Ipsen SA. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Sobre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat